Ptc Therapeutics (PTCT) Total Current Liabilities (2012 - 2026)

Ptc Therapeutics' Total Current Liabilities history runs 15 years deep, the most recent figure standing at $923.6 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 55.13% year-over-year to $923.6 million; the TTM figure through Mar 2026 stood at $923.6 million (up 55.13% YoY), while the FY2025 annual figure was $968.4 million, up 66.69% from the prior year.
• Total Current Liabilities was $923.6 million for Q1 2026 at Ptc Therapeutics, down from $968.4 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $968.4 million in Q4 2025 to a low of $406.2 million in Q4 2022.
• Historically, Total Current Liabilities has averaged $602.4 million across 5 years, with a median of $581.0 million in 2024.
• Biggest YoY gain for Total Current Liabilities was 95.0% in 2022; the steepest drop was 20.24% in 2022.
• A 5-year view of Total Current Liabilities shows it stood at $406.2 million in 2022, then surged by 48.46% to $603.1 million in 2023, then fell by 3.67% to $581.0 million in 2024, then jumped by 66.69% to $968.4 million in 2025, then slipped by 4.63% to $923.6 million in 2026.
• The last three Total Current Liabilities figures came in at $923.6 million (Q1 2026), $968.4 million (Q4 2025), and $866.2 million (Q3 2025), per Business Quant data.